The lawsuits call President Biden’s decision to block the buyout of the American steel maker by Nippon Steel an ‘unlawful political influence.’ ...

PFE ends deal with SGMO for hemophilia A gene therapy candidate. NVS' gene therapy for SMA meets goal in study.

Novartis’ NVS phase III study showed a positive risk-benefit profile of an investigational gene therapy candidate, intrathecal onasemnogene abeparvovec (OAV101 IT), for treating spinal muscular ...

Sangamo is on course to run out of money within months and has now lost access to up to $220 million in milestone payments ...

Jefferies analyst Maury Raycroft lowered the firm’s price target on Sangamo (SGMO) to $3 from $7 and keeps a Buy rating on the shares after the ...

Sangamo Therapeutics regains rights to its hemophilia A gene therapy as Pfizer ends their collaboration. The program showed ...

Sangamo Therapeutics SGMO stock crashed 60.4% after hours on Monday after it announced that its partner, Pfizer PFE, ...

Sangamo Therapeutics said on Monday that partner Pfizer has terminated their hemophilia A gene therapy co-development ...

Below is Validea's guru fundamental report for PFIZER INC (PFE). Of the 22 guru strategies we follow, PFE rates highest using our Shareholder Yield Investor model based on the published strategy ...

In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against the other best dividend leaders to buy. Investors have long been drawn to dividend stocks due to their ...

Below is Validea's guru fundamental report for PFIZER INC (PFE). Of the 22 guru strategies we follow, PFE rates highest using our Shareholder Yield Investor model based on the published strategy ...

Therefore, high-dividend stocks, Pfizer Inc. (PFE), United Parcel Service, Inc. (UPS), and Enterprise Products Partners L.P. (EPD) might be worthy additions before year-end. The annual inflation rate ...